However, application of immunomodulatory drugs including glucocorticosteroids or anti-IL-6 treatment is not standard of care for severe influenza but for severe COVID-19, which may contribute to the elevated risk of pulmonary aspergillosis in critically ill COVID-19 patients. This evidence concerns the gene IL6 and aspergillosis.